• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Neurogene Inc. - Common Stock (NQ:NGNE)

16.81 -0.47 (-2.72%)
Streaming Delayed Price Updated: 1:57 PM EST, Jan 13, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 124,139
Open 17.26
Bid (Size) 16.73 (700)
Ask (Size) 16.89 (200)
Prev. Close 17.28
Today's Range 16.47 - 17.30
52wk Range 6.875 - 37.27
Shares Outstanding 42,425,071
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Neurogene Announces Recent Achievements and Anticipated 2026 Key Milestones for NGN-401, a Potential Best-in-Class Gene Therapy for Rett Syndrome
January 12, 2026
From Neurogene Inc.
Via Business Wire
News headline image
Neurogene to Participate in the 44th Annual J.P. Morgan Healthcare Conference
January 05, 2026
From Neurogene Inc.
Via Business Wire

Performance

YTD
-16.6%
-16.6%
1 Month
-17.0%
-17.0%
3 Month
-46.8%
-46.8%
6 Month
-24.5%
-24.5%
1 Year
-10.6%
-10.6%

More News

Read More
News headline image
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 04, 2025
From Neurogene Inc.
Via Business Wire
News headline image
Neurogene Reports Third Quarter 2025 Financial Results and Highlights Recent Updates
November 13, 2025
From Neurogene Inc.
Via Business Wire
News headline image
Neurogene Reports Positive Interim Data in Pediatric Cohort from NGN-401 Gene Therapy Trial for Rett Syndrome
November 12, 2025
From Neurogene Inc.
Via Business Wire
News headline image
Neurogene Announces First Participant Dosed in Embolden™ Registrational Trial of NGN-401 Gene Therapy for Rett Syndrome
November 06, 2025
From Neurogene Inc.
Via Business Wire
News headline image
Neurogene Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
November 05, 2025
From Neurogene Inc.
Via Business Wire
News headline image
FDA's Rigid Approach Adds Uncertainty To uniQure's Accelerated Pathway For Huntington's Gene Therapy ↗
November 04, 2025
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's Intraday Session ↗
October 09, 2025
Via Benzinga
News headline image
Neurogene Announces Positive Regulatory Update for NGN-401 Gene Therapy in Rett Syndrome with Plans to Initiate Dosing in Embolden™ Registrational Trial in Q4 2025
October 09, 2025
From Neurogene Inc.
Via Business Wire
News headline image
Neurogene to Participate in H.C. Wainwright Genetic Medicines Virtual Conference
October 08, 2025
From Neurogene Inc.
Via Business Wire
News headline image
4 Biotech Stocks Seeing Explosive Momentum Gains ↗
October 07, 2025
Via Benzinga
Topics ETFs Stocks
News headline image
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 03, 2025
From Neurogene Inc.
Via Business Wire
News headline image
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 05, 2025
From Neurogene Inc.
Via Business Wire
News headline image
FDA Outlines Process To Speed Up Rare Disease Therapy Approvals ↗
September 04, 2025
Via Benzinga
News headline image
Neurogene Reports Second Quarter 2025 Financial Results and Highlights Recent Updates
August 11, 2025
From Neurogene Inc.
Via Business Wire
News headline image
Vinay Prasad's Comeback To FDA Sparks Debate Over Regulatory Direction ↗
August 11, 2025
Via Benzinga
News headline image
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 08, 2025
From Neurogene Inc.
Via Business Wire
News headline image
What's Going On With Sarepta, Capricor And Other Gene Therapy Stocks On Wednesday? ↗
July 30, 2025
Via Benzinga
News headline image
12 Health Care Stocks Moving In Friday's After-Market Session ↗
July 11, 2025
Via Benzinga
News headline image
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 03, 2025
From Neurogene Inc.
Via Business Wire
News headline image
Which stocks are moving on Tuesday? ↗
July 01, 2025
Via Chartmill
News headline image
12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
July 01, 2025
Via Benzinga
News headline image
Which stocks are experiencing notable movement on Tuesday? ↗
July 01, 2025
Via Chartmill
News headline image
Neurogene Announces Registrational Trial Design for Embolden™ Study of NGN-401 Gene Therapy for Rett Syndrome
June 30, 2025
From Neurogene Inc.
Via Business Wire

Frequently Asked Questions

Is Neurogene Inc. - Common Stock publicly traded?
Yes, Neurogene Inc. - Common Stock is publicly traded.
What exchange does Neurogene Inc. - Common Stock trade on?
Neurogene Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Neurogene Inc. - Common Stock?
The ticker symbol for Neurogene Inc. - Common Stock is NGNE on the Nasdaq Stock Market
What is the current price of Neurogene Inc. - Common Stock?
The current price of Neurogene Inc. - Common Stock is 16.81
When was Neurogene Inc. - Common Stock last traded?
The last trade of Neurogene Inc. - Common Stock was at 01/13/26 01:57 PM ET
What is the market capitalization of Neurogene Inc. - Common Stock?
The market capitalization of Neurogene Inc. - Common Stock is 713.17M
How many shares of Neurogene Inc. - Common Stock are outstanding?
Neurogene Inc. - Common Stock has 713M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap